ArticleBMC microbiology2026
Enhanced antibiofilm activity of ciprofloxacin-loaded quatsomal gel against Multidrug-Resistant Staphylococcus aureus (MRSA).
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMRSA biofilms remain a major challenge in clinical settings because they reduce antibiotics susceptibility and contribute to persistent infections. This current study was designed to evaluate quatsomal gel as a proof-of-concept topical ciprofloxacin delivery platform aimed at enhancing localized antimicrobial and antibiofilm activity against MRSA. The ciprofloxacin loaded quatsomes were prepared using a probe-sonication method with CTAB and cholesterol and were then incorporated in a hydroxypropyl methylcellulose-based gel.
resultsThe resulting formulation was characterized by particle size, zeta potential, TEM, entrapment efficiency, and FTIR spectroscopy. A HPMC-based gel was developed for topical delivery and its antimicrobial and antibiofilm activities were assessed. An in vivo wound excision model in mice was used to evaluate the therapeutic efficacy of this formulation. The loaded formulation exhibited a mean particle size of 153 ± 1.3 nm, a zeta potential of + 34.6 ± 1.4 mV, and 79 ± 0.4% ciprofloxacin entrapment efficiency. FTIR confirmed drug incorporation, while the pH, spreadability, and viscosity were remained within appropriate ranges for skin application. The optimized formulation significantly reduced MRSA growth, with a minimum inhibitory concentration of 64 µg/mL and 91.32 ± 0.14% biofilm inhibition. In vivo studies showed that the ciprofloxacin-loaded quatsomes treated group had 98% wound contraction and ~ -4 log
conclusionCiprofloxacin-loaded quatsomes showed significant antimicrobial and antibiofilm activity against MRSA in both in vitro and in vivo analysis, representing a promising proof-of-concept approach for localized ciprofloxacin delivery in biofilm-associated skin infections. Further studies should focus on pharmacokinetic evaluation, safety profiling and clinical evaluation to facilitate translation into an effective nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.